DPP-26 Stats & Data

Identity/purity uncertainty: DPP‑26 is very new to the grey market; vendors have reportedly copied potency claims from dipipanone. Submit samples to a drug‑checking service when possible, and assume unknown potency until lab‑verified. Large variability in active dose has been reported within and between batches. Severe nasal causticity has been described with insufflation; users reported intense burn and irritation. From a harm‑reduction standpoint, avoid IN and especially IV routes; oral is the least risky ROA for uncertain powders. At least one user reported injection burning on a miss and only partial solubility until heating; sterile technique and proper filtration cannot eliminate unknown excipients or caustic pH risks. Compared to methiodone/IC‑26 and dipipanone, several reports describe a quicker onset than methiodone but shorter overall duration (~6–10 h), with prominent sedation and modest euphoria. Redose conservatively and wait at least 3 hours after any meaningful oral dose because peaks can be delayed; stacking increases overdose risk. Co‑use with other depressants (alcohol, benzodiazepines, GHB/GBL, gabapentinoids) markedly increases the risk of respiratory depression and fatal overdose; avoid these combinations. Potentiation by antihistamines has a history of serious harm: cyclizine can intensify opioid effects and has been linked to dangerous practices with dipipanone mixtures; avoid sedating antihistamines with DPP‑26. Methadone and some opioids can prolong QT; it is unknown if DPP‑26 does, but until pharmacology is characterized, avoid concurrent QT‑prolonging drugs/electrolyte disturbances and seek medical advice if you have cardiac risk factors. Carry naloxone and ensure others know how to use it; sedation can persist into the next day. Expect typical opioid adverse effects: constipation, pruritus, miosis, nausea; mitigate constipation proactively and avoid driving or hazardous work the day of dosing and until completely alert. Immunoassay cross‑reactivity with methadone panels is unknown; given structural similarity to methiodone/dipipanone analogues, a false positive for methadone cannot be excluded; confirmatory testing (GC‑MS/LC‑MS) would be needed.